HomeCompareBOVNF vs GBDC

BOVNF vs GBDC: Dividend Comparison 2026

BOVNF yields 60.82% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.10M in total portfolio value· pulled ahead in Year 7
10 years
BOVNF
BOVNF
● Live price
60.82%
Share price
$3.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$678.1K
Annual income
$160,128.39
Full BOVNF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — BOVNF vs GBDC

📍 GBDC pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBOVNFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BOVNF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BOVNF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BOVNF
Annual income on $10K today (after 15% tax)
$5,169.37/yr
After 10yr DRIP, annual income (after tax)
$136,109.13/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,794,764.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BOVNF + GBDC for your $10,000?

BOVNF: 50%GBDC: 50%
100% GBDC50/50100% BOVNF
Portfolio after 10yr
$10.73M
Annual income
$8,274,695.89/yr
Blended yield
77.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

BOVNF
No analyst data
Altman Z
10.4
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BOVNF buys
0
GBDC buys
0
No recent congressional trades found for BOVNF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBOVNFGBDC
Forward yield60.82%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$678.1K$20.78M
Annual income after 10y$160,128.39$16,389,263.41
Total dividends collected$563.7K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: BOVNF vs GBDC ($10,000, DRIP)

YearBOVNF PortfolioBOVNF Income/yrGBDC PortfolioGBDC Income/yrGap
1$16,782$6,081.62$12,490$1,790.28+$4.3KBOVNF
2$27,495$9,538.25$16,522$3,157.73+$11.0KBOVNF
3$44,024$14,604.90$23,578$5,898.68+$20.4KBOVNF
4$68,961$21,855.37$37,115$11,886.75+$31.8KBOVNF
5$105,784$31,995.46$66,136$26,423.57+$39.6KBOVNF
6$159,058$45,869.04$137,257$66,491.44+$21.8KBOVNF
7← crossover$234,649$64,457.18$341,734$194,868.54$107.1KGBDC
8$339,944$88,869.20$1,050,788$685,133.02$710.8KGBDC
9$484,065$120,324.94$4,099,314$2,974,971.01$3.62MGBDC
10$678,078$160,128.39$20,775,530$16,389,263.41$20.10MGBDC

BOVNF vs GBDC: Complete Analysis 2026

BOVNFStock

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

Full BOVNF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this BOVNF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BOVNF vs SCHDBOVNF vs JEPIBOVNF vs OBOVNF vs KOBOVNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.